全文获取类型
收费全文 | 230750篇 |
免费 | 20696篇 |
国内免费 | 10752篇 |
专业分类
耳鼻咽喉 | 2454篇 |
儿科学 | 4987篇 |
妇产科学 | 2604篇 |
基础医学 | 41313篇 |
口腔科学 | 5972篇 |
临床医学 | 17908篇 |
内科学 | 37896篇 |
皮肤病学 | 5348篇 |
神经病学 | 11907篇 |
特种医学 | 4908篇 |
外国民族医学 | 124篇 |
外科学 | 18006篇 |
综合类 | 35435篇 |
现状与发展 | 65篇 |
预防医学 | 9979篇 |
眼科学 | 3913篇 |
药学 | 20915篇 |
45篇 | |
中国医学 | 8325篇 |
肿瘤学 | 30094篇 |
出版年
2024年 | 377篇 |
2023年 | 2945篇 |
2022年 | 5297篇 |
2021年 | 7994篇 |
2020年 | 7183篇 |
2019年 | 7267篇 |
2018年 | 7336篇 |
2017年 | 7595篇 |
2016年 | 8235篇 |
2015年 | 9304篇 |
2014年 | 14031篇 |
2013年 | 15237篇 |
2012年 | 13768篇 |
2011年 | 15177篇 |
2010年 | 12529篇 |
2009年 | 12031篇 |
2008年 | 12397篇 |
2007年 | 12565篇 |
2006年 | 11408篇 |
2005年 | 10274篇 |
2004年 | 8976篇 |
2003年 | 7748篇 |
2002年 | 6362篇 |
2001年 | 5496篇 |
2000年 | 4463篇 |
1999年 | 4001篇 |
1998年 | 3725篇 |
1997年 | 3347篇 |
1996年 | 2947篇 |
1995年 | 2654篇 |
1994年 | 2331篇 |
1993年 | 1919篇 |
1992年 | 1622篇 |
1991年 | 1466篇 |
1990年 | 1177篇 |
1989年 | 1090篇 |
1988年 | 1013篇 |
1987年 | 814篇 |
1986年 | 745篇 |
1985年 | 1183篇 |
1984年 | 1124篇 |
1983年 | 841篇 |
1982年 | 865篇 |
1981年 | 699篇 |
1980年 | 617篇 |
1979年 | 507篇 |
1978年 | 376篇 |
1977年 | 290篇 |
1976年 | 278篇 |
1975年 | 192篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
《药学学报(英文版)》2020,10(7):1294-1308
A great challenge in multi-targeting drug discovery is to identify drug-like lead compounds with therapeutic advantages over single target inhibitors and drug combinations. Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency. Particularly, compound 30a was orally active and possessed excellent in vivo antitumor activity in the HCT116 xenograft model (TGI = 75.2%, 150 mg/kg, p.o.) without significant toxicity, which was more potent than HDAC inhibitor vorinostat, TOP inhibitor evodiamine and their combination. Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents. 相似文献
103.
张献彩 《山西医科大学学报》2015,(1)
目的:观察糖尿病小鼠小肠绒毛杯状细胞分泌的黏原颗粒是否改变,为进一步研究糖尿病的消化系统并发症提供形态学基础。方法分别选取3,5,8,10月龄db/db糖尿病小鼠及相应年龄段的db/+m正常小鼠,每组6只,标本用4%多聚甲醛灌流固定后,从距Treitz韧带约10 cm处切下一段空肠,用PAS染色方法对小肠杯状细胞分泌的黏原颗粒进行观察。结果糖尿病组小肠绒毛易被破坏,糖尿病组中杯状细胞的分泌物比同月份正常对照组显著增加(P<0.05);糖尿病组中3月龄的杯状细胞分泌物最多,8月龄最少,并且8月龄分别与3月龄、5月龄比较均存在着显著差异(P<0.05);正常对照组随月龄增长无显著性差异(P>0.05)。结论糖尿病时杯状细胞分泌物增多可能对小肠绒毛有保护作用。 相似文献
104.
《Cancer cell》2021,39(11):1497-1518.e11
- Download : Download high-res image (282KB)
- Download : Download full-size image
105.
随着对肿瘤热疗和肿瘤免疫微环境(TIME)的深入研究,近年来热疗对TIME的作用越来越受到学者们的重视。本文就目前国内外研究进展,对热疗与TIME中几类主要免疫细胞和免疫相关细胞因子的影响及作用机制作一综述。全面而透彻的了解热疗对TIME的调控作用,有助于为肿瘤治疗提供新的思路和方法。 相似文献
106.
107.
108.
《Vaccine》2016,34(24):2663-2670
Human metapneumovirus (HMPV) is a major cause of morbidity and mortality from acute lower respiratory tract illness, with most individuals seropositive by age five. Despite the presence of neutralizing antibodies, secondary infections are common and can be severe in young, elderly, and immunocompromised persons. Preclinical vaccine studies for HMPV have suggested a need for a balanced antibody and T cell immune response to enhance protection and avoid lung immunopathology. We infected transgenic mice expressing human HLA-A*0201 with HMPV and used ELISPOT to screen overlapping and predicted epitope peptides. We identified six novel HLA-A2 restricted CD8+ T cell (TCD8) epitopes, with M39–47 (M39) immunodominant. Tetramer staining detected M39-specific TCD8 in lungs and spleen of HMPV-immune mice. Immunization with adjuvant-formulated M39 peptide reduced lung virus titers upon challenge. Finally, we show that TCD8 from HLA-A*0201 positive humans recognize M39 by IFNγ ELISPOT and tetramer staining. These results will facilitate HMPV vaccine development and human studies. 相似文献
109.
《Molecular therapy》2020,28(6):1432-1441
- Download : Download high-res image (155KB)
- Download : Download full-size image
110.
《Vaccine》2016,34(46):5677-5688
Mycobacterium tuberculosis (Mtb), the bacterial cause of tuberculosis, is a leading infectious agent worldwide. The development of a new vaccine against Mtb is essential to control global spread of tuberculosis, since the current vaccine BCG is not very effective and antibiotic resistance is a serious, burgeoning problem. ESAT-6 is a secreted protein of Mtb, which is absent in BCG but has been implicated in inducing protective immunity against Mtb. Peptide based subunit vaccines are attractive due to their safety and high specificity in eliciting immune responses, but small synthetic peptides are usually not very immunogenic. We have designed a novel subunit vaccine for Mtb by using simple lipid (palmitic acid) modified derivatives of peptides from ESAT-6 protein corresponding to dominant human T cell epitopes and examined their ability to stimulate protective immunity against Mtb by intranasal and subcutaneous immunization in mice. We also investigated how individual TLR agonists as adjuvants (PolyI:C, MPL and GDQ) contribute to enhancing the induced immune responses and resulting protective efficacy of our vaccine. We observed that single C-terminal palmitoyl-lysine modified lipopeptides derived from ESAT-6 induce significant cellular immune responses on their own upon mucosal and subcutaneous immunizations. Intriguingly, a combination of immunogenic lipopeptides of ESAT-6 antigen exhibited local (pulmonary) and systemic immune responses along with efficient protective efficacy when administered intranasally or subcutaneously. Surprisingly, combination of ESAT-6 derived lipopeptides with a TLR-4 agonist (MPL) enhanced protection, whereas TLR-3 (Poly I:C) and TLR-7/8 agonists (gardiquimod, GDQ) led to reduced protection associated with specific local and systemic immune modulation. Our studies demonstrate the potential of ESAT-6 derived lipopeptides as a promising vaccine candidate against Mtb, and emphasize that selection of adjuvant is critical for the success of vaccines. These findings demonstrate the promise of synthetic lipopeptides as the basis of a subunit vaccine for TB. 相似文献